Department of General Surgery, Central Michigan University College of Medicine, Mt Pleasant, MI.
Division of Thoracic Surgery, Department of Cardiothoracic Surgery, Weill Cornell Medicine-New York Presbyterian Hospital, New York, NY.
Ann Surg. 2023 Apr 1;277(4):e772-e776. doi: 10.1097/SLA.0000000000005197. Epub 2021 Sep 1.
The aim of this study was to explore the potential value of extended nodal-dissection following neoadjuvant chemoradiation (CRT), by analyzing data from the National Cancer Database (NCDB).
A CROSS-trial post-hoc analysis showed that the number of dissected lymph nodes was associated with improved survival in patients undergoing upfront surgery but not in those treated with neoadjuvant CRT.
The NCDB was queried (2004-2014) for patients who underwent esophagectomy following induction CRT. Predictors of overall survival (OS) were assessed. The optimal number of dissected LNs associated with highest survival benefit was determined by multiple regression analyses and receiveroperating characteristic curve analysis. The whole cohort was divided into 2 groups based on the predefined cutoff number. The two groups were propensity-matched (PMs).
Esophagectomy following induction-CRT was performed in 14,503 patients. The number of resected nodes was associated with improved OS in the multivariable analysis (hazard ratio for every 10 nodes: 0.95 (95% confidence interval: 0.93-0.98). The cutoff number of resected LNs that was associated with the highest survival benefit was 20 nodes. In the PM groups, patients in the "≥20 LNs" group had a 14% relative-increase in OS ( P = 0.002), despite having more advanced pathological stages (stage II-IV: 76% vs 72%, P < 0.001), and higher number of positive nodes (0-2 vs 0-1, P < 0.001).
The total number of resected nodes is a significant determinant of improved survival following induction CRT in patients with either node negative or node positive disease. In the matched groups, patients with higher number of resected lymph nodes had higher OS rate, despite having more advanced pathological disease and higher number of resected positive lymph nodes.
本研究旨在通过分析国家癌症数据库(NCDB)的数据,探讨新辅助放化疗(CRT)后扩大淋巴结清扫的潜在价值。
一项跨试验事后分析显示,在接受 upfront 手术的患者中,淋巴结清扫数量与生存改善相关,但在接受新辅助 CRT 治疗的患者中则不相关。
从 2004 年至 2014 年,NCDB 中检索接受 CRT 诱导后行食管癌切除术的患者。评估总生存(OS)的预测因素。通过多元回归分析和接收者操作特征曲线分析确定与最高生存获益相关的最佳淋巴结清扫数量。根据预定义的截断值将整个队列分为 2 组。两组进行倾向匹配(PMs)。
14503 例患者接受 CRT 诱导后行食管癌切除术。多变量分析显示,切除淋巴结的数量与 OS 改善相关(每增加 10 个淋巴结的风险比:0.95(95%置信区间:0.93-0.98))。与最高生存获益相关的最佳淋巴结清扫数量的截断值为 20 个。在 PM 组中,“≥20 个淋巴结”组的患者 OS 相对增加 14%(P=0.002),尽管其具有更晚期的病理分期(Ⅱ-Ⅳ期:76%比 72%,P<0.001)和更多的阳性淋巴结数(0-2 比 0-1,P<0.001)。
在淋巴结阴性或阳性疾病患者中,切除淋巴结的总数是新辅助 CRT 后生存改善的重要决定因素。在匹配组中,尽管具有更晚期的病理疾病和更多切除的阳性淋巴结,但具有更多淋巴结清扫的患者具有更高的 OS 率。